Fucoidan from Saccharina japonica Alleviates Hyperuricemia-Induced Renal Fibrosis through Inhibiting the JAK2/STAT3 Signaling Pathway

• DOI: 10.1021/acs.jafc.3c01349
• Publication Date: 2023-07-23T12:52:15Z
• Authors: Lirui Sun; Qing Liu; Yabin Zhang; Meilan Xue; Hongxue Yan; Xia Qiu; Yingjie Tian; Huaqi Zhang; Hui Liang
• Keywords: Fucoidan

Fucoidan is a native sulfated polysaccharide mainly isolated from brown seaweed, with diverse pharmacological activities, such as anti-inflammatory and antifibrosis. Hyperuricemia (HUA) common metabolic disease worldwide causes hyperuricemic nephropathy, including chronic kidney end-stage renal fibrosis. The present study investigated the protective function of fucoidan in fibrosis its mechanism. fibrotic model was established administration potassium oxonate for 10 weeks. protein levels related factors were assessed HUA mice by an enzyme-linked immunosorbent assay (ELISA) western blotting. results showed that significantly reduced serum uric acid, blood urea nitrogen (BUN), α-smooth muscle actin (α-SMA), collagen I, improved pathological changes. Furthermore, had been remarkably elevated through inhibition epithelial-to-mesenchymal transition (EMT) progression after intervention, suppressing Janus kinase 2 (JAK2) signal transducer activator transcription 3 (STAT3) signaling pathway activation. Together, this provides experimental evidence may protect against hyperuricemia-induced via downregulation JAK2/STAT3 pathway.